Deutsche Bank
TRVI icon

Deutsche Bank’s Trevi Therapeutics TRVI Stock Holding History

Deutsche Bank’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.01M Buy
84,755
+13,922
+20% +$156K ﹤0.01% 2175
2025
Q4 		$887K Buy
70,833
+19,193
+37% +$222K ﹤0.01% 2247
2025
Q3 		$473K Buy
51,640
+8,203
+19% +$61.5K ﹤0.01% 2571
2025
Q2 		$238K Buy
43,437
+5,811
+15% +$36.2K ﹤0.01% 2865
2025
Q1 		$237K Buy
37,626
+8,383
+29% +$40K ﹤0.01% 2877
2024
Q4 		$120K Buy
29,243
+685
+2% +$2.19K ﹤0.01% 3242
2024
Q3 		$95.4K Buy
28,558
+14,635
+105% +$43.5K ﹤0.01% 3233
2024
Q2 		$41.5K Sell
13,923
-3,894
-22% -$10.8K ﹤0.01% 3355
2024
Q1 		$61.5K Buy
+17,817
New +$39.8K ﹤0.01% 3345
2023
Q4 		– Sell
-25,070
Closed -$54.7K – 3703
2023
Q3 		$54.7K Buy
+25,070
New +$56.6K ﹤0.01% 3389

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return